Stocktoria
IMMUNIC, INC. IMUX
IMMUNIC, INC. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D expense | $82.0M | $80.0M | $83.2M | $71.3M | $61.1M | $38.6M | $22.5M | $9.6M | $39.3M | $30.0M |
| Operating income | -$103.2M | -$98.1M | -$99.2M | -$119.5M | -$91.7M | -$49.0M | -$37.0M | -$12.0M | -$52.7M | -$41.3M |
| Income tax | $0 | — | — | — | — | — | — | — | — | — |
| Net income | -$97.2M | -$100.5M | -$93.6M | -$120.4M | -$92.9M | -$44.0M | -$34.9M | -$11.5M | -$52.1M | -$41.0M |
| EPS (diluted) | $-0.62 | $-1.00 | $-2.11 | $-3.78 | $-3.93 | $-2.81 | — | — | — | — |
| Operating cash flow | -$85.8M | -$84.8M | -$70.8M | -$65.1M | -$83.2M | -$46.1M | -$28.5M | -$9.7M | -$40.4M | -$35.8M |
| Free cash flow | -$86.0M | -$85.0M | -$71.2M | -$65.3M | -$83.3M | -$46.3M | -$28.6M | -$9.8M | -$41.1M | -$36.3M |
| Cash & equivalents | $15.5M | $35.7M | $46.7M | $106.7M | $86.9M | $127.5M | $29.4M | $13.1M | $56.9M | $60.0M |
| Total assets | $24.1M | $40.9M | $54.3M | $127.8M | $139.1M | $167.9M | $66.0M | $13.4M | $60.4M | $64.0M |
| Total liabilities | $30.7M | $22.4M | $25.4M | $14.1M | $12.0M | $9.1M | $7.6M | $1.9M | — | — |
| Shareholders' equity | -$6.7M | $18.4M | $28.9M | $113.7M | $127.1M | $158.8M | $58.4M | -$25.7M | -$13.3M | $58.4M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.